Botox now has new competition with USFDA approving Daxxify as per article below:
With long-awaited FDA nod, Revance set to take on AbbVie’s Botox with its longer-lasting Daxxify
The key differentiator for Daxxify is that it’s anti wrinkle effect is longer lasting than Botox. Daxxify is also being investigated for therapeutic benefits.
From Gufic’s perspective, this may not have any effect in the short/medium term. Gufic is still building it’s brand presence with Stunnox in India and, if executed well, has a lot of market share to grab.